EU gives CE mark approval for Percepta Quad CRT-P for atrial fibrillation- Medtronic

Medtronic has announced that it has received CE Mark approval for a suite of quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla machines. This complete line of CRT-Ps, available in Europe in March, includes the Percepta Quad CRT-P MRI SureScan. These devices are not yet approved for sale in the United States.

The Percepta Quad CRT-P features the EffectivCRT Diagnostic, which automatically determines the effectiveness of each left ventricular pace, and the EffectivCRT during AF algorithm, which automatically adjusts pacing rates during atrial fibrillation (AF), without adversely affecting the average heart rate. It also includes VectorExpress 2.0, an automated in-office test that reduces lead programing to two minutes, and reveals clinically actionable information to help physicians select optimal pacing configurations for each patient. The Percepta Quad and Serena Quad CRT-Ps also feature the Medtronic-exclusive AdaptivCRT algorithm, which reduces a patient's odds of a 30-day heart failure readmission by 59 percent, and has demonstrated a 46 percent reduction in AF risk compared to echo-optimized biventricular pacing. Both devices also feature Multiple Point Pacing, which can stimulate two sites on the left ventricle (lower chamber) simultaneously or sequentially.